HSCT


Also found in: Acronyms.

HSCT

Abbreviation for hemotopoietic stem cell transplant.
Mentioned in ?
References in periodicals archive ?
Participants in the SCOT trial, conducted at 26 clinical research sites in the United States and Canada, were randomly assigned to receive either myeloablative autologous HSCT or one year of treatment with monthly doses of intravenous cyclophosphamide.
These late effects "can significantly impact patients' quality of life," according to the authors, who called for larger studies that follow pediatric HSCT patients longitudinally, beginning before the transplant--and for more investigation into the pathogenesis of specific late effects.
12-14) In a prospective trial with routine screening of laboratory markers, 39% of HSCT recipients were found to meet the diagnosis of TA-TMA.
bieneusi microsporidiosis in allogeneic HSCT recipients who were treated with fumagillin without modifying the immunosuppressive regimen for 1 recipient.
The present study retrospectively evaluated FN attacks in HSCT recipients during the period of June 2014 - January 2015 at our HSCT clinic.
This is a very risky, very complex procedure" that should only be performed at highly specialized centers that have expertise both in HSCT and in the management of MS, and that have a very good track record for safety both during and after the transplant, Dr.
She lost her hair and had extreme fatigue but since the HSCT, she no longer suffers pain or cramp in her legs on waking up, she can climb stairs more easily and has more energy.
However, trials have found that while HSCT may be able to stabilise or improve disability in some people with MS it may not be effective for those with all types of the condition.
We present a case of tacrolimus toxicity secondary to supratherapeutic drug levels in a postallogeneic HSCT patient using inhaled and edible marijuana.
In HSCT recipients and patients with hematologic malignancies, progression from URTI to LRTI is estimated to occur in 13% to 43% of cases, whereas mortality rates from PIV LRTI are reported between 12% and 50% [3].
The present study investigated the treatment with rFVIIa in severe GI bleeding among thrombocytopenia patients undergoing HSCT.